Kwashiorkor

2

Review clinical trials related to Kwashiorkor. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Choline to Improve Malnutrition and Enhance Cognition

The goal of this clinical trial is to test adding choline to ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition (SAM) in Malawi. The main question it aims to answer is: \- Will the addition of a 500mg daily dose of choline to RUTF during treatment for SAM improve cognitive development among 6-59-month-old Malawian children compared with standard RUTF without added choline?

Participants needed: 1,500
Trial details
Age: 6-59Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Mar 17, 2026Locations: 10
Eligibility criteria

6-59 months of age [+2]

features of complicated SAM: inability to tolerate a 30g test dose of RUTF, brea... [+5]

Status: Recruiting

Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition

The goal of this clinical trial is to test the use of milk fat globule membrane (MFGM) in ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition in Sierra Leone. The main questions it aims to answer are: * Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition improve their neurodevelopment? * Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition reduce its worst consequences: death, hospitalization, and remaining severely malnourished despite treatment? Researchers will compare the MFGM-containing RUTF to standard RUTF, which contains skim milk powder. Participants will: * undergo measurement of length, weight, mid-upper arm circumference, and nutritional edema assessment every two weeks during severe malnutrition treatment * be treated with either MFGM-RUTF or standard RUTF at a dose of 2 sachets per day for up to 12 weeks * undergo neurodevelopmental testing using the Malawi Developmental Assessment Tool at the end of SAM treatment and 6 months later * a subset of participants will undergo blood spot collection and stool sample collection

Participants needed: 1,600
Trial details
Age: 6-59Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Dec 17, 2025Locations: 10
Eligibility criteria

6-59 months of age [+3]

Features of complicated SAM: inability to tolerate a 30 g test dose of RUTF, bre... [+4]